ISTH interim guidance on recognition and management of coagulopathy in COVID-19
The COVID-19 outbreak has now spread worldwide, and the number of severe cases is increasing exponentially. Besides the...
AUTHORS
Editor in chief - Anna Falanga
Professor of hematology, University of Milano-Bicocca, Department of Medicine and Surgery, Milan and Hospital Papa Giovanni XXIII, Bergamo, Italy.
Anna Falanga, MD, is Chief of the Department of Immunohematology and Transfusion Medicine and the Thrombosis and Hemostasis Center, at the Hospital Papa Giovanni XXIII, in Bergamo, Italy. Author of more than 280 publications and guest editor of 15 volumes, she is appointed as professor at the School of Hematology, University Bicocca Milan, and at the faculty of Health Engineering, University of Bergamo, Italy. She sits on board of the Council of the International Society of Thrombosis and Haemostasis (ISTH). In 2009 she received the BACH Investigator Award of the ISTH, and in 2015 the "Harold R. Roberts Medal 2015" of the SSC of ISTH.
Other activities of Anna Falanga include the organization of numerous scientific conferences, including the co-chairmanship of International Conferences on "Thrombosis and Hemostasis Issues in Cancer" (ICTHIC).
Anna Falanga, MD, is Chief of the Department of Immunohematology and Transfusion Medicine and the Thrombosis and Hemostasis Center, at the Hospital Papa Giovanni XXIII, in Bergamo, Italy. Author of more than 280 publications and guest editor of 15 volumes, she is appointed as professor at the School of Hematology, University Bicocca Milan, and at the faculty of Health Engineering, University of Bergamo, Italy. She sits on board of the Council of the International Society of Thrombosis and Haemostasis (ISTH). In 2009 she received the BACH Investigator Award of the ISTH, and in 2015 the "Harold R. Roberts Medal 2015" of the SSC of ISTH.
Other activities of Anna Falanga include the organization of numerous scientific conferences, including the co-chairmanship of International Conferences on "Thrombosis and Hemostasis Issues in Cancer" (ICTHIC).
Platelet Cut-Off for Anticoagulant Therapy in Thrombocytopenic Patients with Blood Cancer and Venous Thromboembolism
Venous thromboembolism (VTE) is a recurrent risk factor in cancer patients. In particular, patients with hematologic...
Venous thromboembolism: News from the Annual Meeting of the American Society of Hematology (ASH) on prevention and treatment
The Annual Meeting of the American Society of Hematology (ASH) was held on 7−10 December 2019 in Orlando (FL, USA)....
Making cancer-related complications and comorbidities an EU health priority: a joint statement from the European Thrombosis and Haemostasis Alliance (ETHA)
Cancer represents the second most important cause of death and morbidity in Europe, with more than 3.7 million new...
Looking for a reliable tool to identify hypercoagulant markers for cancer risk and prognosis: the HYPERCAN study
The HYPERCAN (HYPERcoagulation in CANcer) study (registered at www.clinicaltrials.gov; NCT02622815) is an ongoing,...
Venous thromboembolism in patients with solid tumors: the Italian Association of Medical Oncology (AIOM) guidelines 2019
The latest guidelines for venous thromboembolism in patients with solid tumors from the Italian Association of Medical...
ISTH 2018 – Anna Falanga
Anna Falanga Chief of the Department of Immunohematology and Transfusion Medicine and the Thrombosis and Hemostasis...